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Abstract 
Background: Carbapenem resistance among the Enterobacteriaceae is a serious healthcare challenge. blaIMI is a 
carbapenemase gene mediating resistance to carbapenems but has not been commonly found. A blaIMI-carrying 
Enterobacter cloacae, which was also resistant to colistin, is reported here.
Findings: E. cloacae strain WCHECl-1060 was recovered from a blood sample of a leukemia patient, who was not 
previously exposed to colistin. Strain WCHECl-1060 belongs to a new sequence type, ST410, and was resistant to car-
bapenems and colistin but was susceptible to third-generation cephalosporins. A new allelic variant of blaIMI-1, which 
has two silent mutations compared to the original blaIMI-1 variant, was found in strain WCHECl-1060. Conjugation and 
transformation experiments failed to transfer blaIMI-1, suggesting a likely chromosome origin.
Conclusions: To our knowledge, this is the first report of an IMI-1 carbapenemase-producing colistin-resistant E. cloa-
cae in China. Microbiological laboratories should be aware of the unusual carbapenem-resistant but third-generation 
cephalosporin-susceptible profiles of these IMI-producing isolates. The trend of colistin resistance among the Entero-
bacteriaceae should be also monitored.
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Findings
Enterobacter cloacae strain WCHECl-1060 was recov-
ered from the blood of a 30-year-old male patient with 
acute lymphoblastic leukemia in our hospital on Octo-
ber 2014. Species identification was performed using the 
Vitek II automated system (bioMerieux, Lyon, France) 
and was also confirmed by partially sequencing the gyrB 
gene as described previously [1]. In vitro susceptibil-
ity tests were performed using the Vitek II system and 
minimum inhibitory concentrations (MICs) of amikacin, 
ceftazidime, ciprofloxacin, colistin, imipenem and tige-
cycline were also determined using the microdilution 
broth method followed recommendations of the Clinical 
Laboratory Standards Institute [2]. Strain WCHECl-1060 
was susceptible to ceftazidime (MIC 1  μg/mL), amika-
cin (MIC 4  μg/mL), ciprofloxacin (MIC 8  μg/mL) and 
tigecycline (MIC 4  μg/mL) but resistant to imipenem 
(MIC 256 μg/mL) and colistin (MIC >256 μg/mL). Strain 
WCHECl-1060 was also susceptible to aztreonam, ceftri-
axone, cefepime, piperacillin–tazobactam, gentamicin, 
tobramycin, levofloxacin, trimethoprim–sulphamethoxa-
zole and minocycline, intermediate to nitrofurantoin and 
cefotetan, and resistant to meropenem and ertapenem as 
determined by Vitek II.
Strain WCHECl-1060 was screened using PCR 
for blaIMI with in-house designed primers IMI-Fn 
(AGAGTTCYATTCACCCATCACA) and IMI-Rn 
(TCTCCAATCGACCGCATGAA) and for other 
acquired carbapenemase-encoding genes blaGES, blaKPC, 
blaIMP, blaNDM, blaOXA-48 and blaVIM as described pre-
viously [3–6]. blaIMI was the only carbapenemase gene 
detected in strain WCHECl-1060. The complete cod-
ing sequence of blaIMI was further amplified with an 
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additional pair of in-house designed primers, IMI-up 
(CTGGCACGCATAGTAACCCA) and IMI-dw (ATGC-
CGAAAGTGCAAGCCT). Sequencing of the amplicon 
revealed the presence of blaIMI-1. Of note, the blaIMI-1 
gene identified here had two silent mutations (T201C 
and C459T, positions assigned with respect to the ATG 
start codon of the blaIMI-1 gene) compared to the origi-
nal blaIMI-1 gene (GenBank accession number U50278) 
found in the USA and has one silent mutation (T201C) to 
another blaIMI-1 variant (GenBank accession JX090311) 
found in Taiwan. In total, three types of blaIMI-1 have 
been found so far and the blaIMI-1 gene identified here is a 
new variant whose sequence has been deposited into the 
GenBank under the accession number KP284436.
Strain typing was performed using the multi-locus 
sequence typing (MLST) scheme for E. cloacae (http://
pubmlst.org/ecloacae/). Strain WCHECl-1060 was of a 
new sequence type, ST410, which was assigned by the 
curator of the MLST database.
Conjugation experiments were performed using the 
azide-resistant Escherichia coli strain J53 as the recipi-
ent with potential transconjugants being selected on 
media containing 2  μg/mL imipenem and 150  μg/mL 
sodium azide. Transformation experiments were carried 
out using plasmid DNA prepared from WCHECl-1060 
by alkaline lysis, which was electroporated into E. coli 
strain DH5α with potential transformants being selected 
on media containing 2 μg/mL imipenem. Both conjuga-
tion and transformation experiments failed to transfer 
carbapenem resistance, suggesting that blaIMI-1 was likely 
located on the chromosome. This result was not surpris-
ing considering that most blaIMI genes found so far are 
chromosome-borne [7–9].
Currently, there are 11 assigned variants of IMI 
enzymes (IMI-1 to -11, http://www.lahey.org/Studies/
other.asp#table1). In addition, carbapenemase NCM-A 
shares 97 % amino acid identity with IMI-1 and is there-
fore also a type of IMI enzyme. The distribution of IMI-
producing isolates is summarized in Table 1. Two features 
of the distribution of IMI-producing isolates could be 
noticed. First, although IMI/NCM-A type enzymes have 
been reported for 20 years, surprisingly, only a few IMI-
producing isolates have been identified since then. In 
contrast, another Class A carbapenemase, KPC, has been 
commonly found in carbapenem-resistant Enterobac-
teriaceae worldwide. Second, although IMI-producing 
isolates are not common, they have a wide geographic 
distribution having been found in isolates from Asia, 
Europe, and North and South Americas (Table 1). Several 
reasons could be proposed for the scarce identification 
of IMI-producing isolates. IMI has only weak activity 
against third-generation cephalosporins [7] and, based on 
available data, IMI-producing Enterobacter spp. are also 
usually susceptible to ciprofloxacin [10, 11]. As third-
generation cephalosporins and fluoroquinolones are the 
most common antimicrobial agents used for treating 
human infections, the susceptibility of IMI-producing 
isolates to these commonly-used agents may hinder their 
wide dissemination. In addition, genes encoding IMI-1 
and NCM-A are largely found on the chromosome rather 
than carried by plasmids, which may serve as an obstacle 
for horizontal transfer of the genes between strains and 
between species. Nonetheless, the current epidemiologi-
cal pattern of IMI-producing strains have not been fully 
understood and therefore more surveillances for IMI-
producing strains is warranted. The exact origin of IMI 
enzymes and how it emerged in Enterobacter spp. also 
remain unknown.
This is the first report in China of an E. cloacae clini-
cal isolate that carries blaIMI-1 and is resistant to colis-
tin. Nonetheless, three IMI-producing E. cloacae strains 
have previously been found in China. IMI-1 was found 
in Taiwan (GenBank accession number JX090311) but 
no details such as susceptibility are available for the host 
strain. IMI-2 was detected in a single strain in Zhejiang 
Province and IMI-3 was reported from Hong Kong but 
the susceptibility of both strains to colistin has not been 
tested [11, 12].
The resistance to colistin of strain WCHECl-1060 is 
unexpected and worrying as colistin is not available for 
Table 1 The distribution of IMI-producing isolates
a blaIMI-5, -6, -9, -10 and -11 have been assigned but no sequences nor publications 
are available
IMI typea Host species Location Accession 
number
References
1 E. cloacae USA U50278 [7]
E. cloacae Taiwan JX090311
E. cloacae France [8]
E. asburiae Ireland [10]
E. cloacae Canada KR057494
E. cloacae China This study
2 E. coli Spain JN412066 [15]
E. asburiae USA DQ173429 [16]
E. cloacae China AY780889 [12]
3 E. cloacae Hong Kong GU015024 [11]
4 E. cloacae Singapore KF958750
7 E. cloacae Singapore KM103296
8 E. cloacae UK KP081315
NCM-A E. cloacae Argentina AJ536087
E. cloacae Canada KR057492
E. cloacae Canada KR057493
E. cloacae Canada KR057495
E. cloacae Canada KR057496
E. cloacae France Z21956 [9]
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clinical treatment in China, the patient had no expo-
sure to this agent and Enterobacter spp. is not intrinsi-
cally resistant to colistin [13]. Unfortunately, there is no 
national data on the susceptibility of Enterobacter spp. 
to colistin in China. As colistin is expected to become 
available in China soon, monitoring resistance to colis-
tin among the Enterobacteriaceae is required at both 
national and local levels. Resistance to colistin imposes 
a great challenge for treating carbapenem-resistant 
Enterobacteriaceae. However, the mechanism conferring 
resistance to colistin among Enterobacter spp. remains 
largely uninvestigated although a recent study revealed 
resistance to colistin in an E. cloacae strain recovered in 
the USA is associated with cross-resistance to the host 
antimicrobial lysozyme [14]. Further investigation for 
the resistance mechanism of strain WCHECl-1060 is 
warranted.
In conclusion, this is the first report in China of an 
IMI-producing colistin-resistant E. cloacae clinical iso-
late. The unusual resistance profile, i.e. being resistant to 
carbapenems while susceptible to third-generation ceph-
alosporins, of the Enterobacteriaceae should prompt lab-
oratories to be aware of the presence of IMI enzymes. As 
colistin is crucial last resort antimicrobial against infec-
tions caused by Gram-negative bacilli, monitoring resist-
ance to colistin among Enterobacter spp. and studies on 
the colistin-resistance mechanism are much needed to 
combat antimicrobial resistance.
Availability of supporting data
The sequence of the blaIMI-1 variant in this study has been 
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pubmlst.org/ecloacae/).
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